Compound Danshen Dripping Pill inhibits doxorubicin or isoproterenol-induced cardiotoxicity

Area of Science:

• Cardiovascular Research
• Traditional Chinese Medicine
• Pharmacology

Background:

• Heart failure (HF) presents significant morbidity and mortality.
• Compound Danshen Dripping Pill (CDDP) is a widely used Traditional Chinese Medicine for cardiovascular conditions.

Purpose of the Study:

• To investigate the protective effects of CDDP against doxorubicin (DOX) or isoprenaline (ISO)-induced heart failure in mice.
• To elucidate the underlying mechanisms of CDDP's cardioprotective actions.

Main Methods:

• Mice were treated with CDDP followed by DOX or ISO induction of heart failure.
• Cardiac function was assessed using electrocardiography and echocardiography.
• Biochemical parameters, myocardial structure, gene expression (RNAseq, qRT-PCR), and protein levels (Western blot) were analyzed.

Main Results:

• CDDP normalized heart weight changes, HF parameters, and fibrogenesis in DOX/ISO-treated mice.
• CDDP restored left ventricular ejection fraction and fractional shortening impaired by DOX/ISO.
• CDDP inhibited DOX/ISO-induced inflammation, cell apoptosis, and pro-fibrotic molecule expression while enhancing antioxidant enzyme expression.

Conclusions:

• CDDP demonstrates significant cardioprotective effects against various models of myocardial injury.
• CDDP normalizes cardiac function and mitigates pathological changes associated with heart failure.
• These findings suggest CDDP has potential therapeutic applications for treating heart failure.